Immunotherapy Archives

News and Trends 9 Dec 2022

Beyond Biotech podcast 25: Center for Global Development, Humacyte, Transgene

This week, we have three interviews. One is from Bio-Europe, a chat with Transgene chief business officer, Steven Bloom, and we also have conversations with Humacyte CEO Laura Niklason, and with Anthony McDonnell, Senior Policy Analyst at the Center for Global Development, on the subject of antimicrobial resistance. We also have our weekly commentary from […]

December 9, 2022

News and Trends 7 Dec 2022

Touchlight and Odimma Therapeutics sign deal to develop personalized cancer therapy

Touchlight, a biotechnology company pioneering enzymatic DNA production to enable genetic medicines, has signed a development and supply agreement with Odimma Therapeutics, a French biotech company focusing on personalized cancer immunotherapy. The agreement focuses on the provision of clinical material for use in Odimma’s oncological neoantigen program. Through the deal, Odimma will gain access to […]

December 7, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 6 Dec 2022

Pictor receives $5M in funding for Covid antibody test and human and animal portfolios

Pictor, a global leader in immunodiagnostics, has announced a $5 million funding round to help accelerate pipeline product development projects. The company will also use the funding for market development activities within Australia and New Zealand, the U.S. and Europe for its human health and animal health portfolios. This follows a June funding round raising […]

December 6, 2022 - 3 minutesmins - By Liza Laws

News and Trends 28 Nov 2022

Lyvgen and Bristol Myers Squibb commitment to transform cancer care

Lyvgen Biopharma announced yesterday that it has started a phase 2 trial of LVGN7409 plus docetaxel or, in collaboration with Bristol Myers Squibb, nivolumab in patients with advanced/metastatic non-small cell lung cancer (NSCLC). “Lyvgen clinical collaboration with Bristol Myers Squibb underscores our commitment to exploring combination regimens from our portfolio with complementary mechanisms of action […]

November 28, 2022 - 3 minutesmins - By Liza Laws

News and Trends 28 Nov 2022

Licensing agreement signed for C4XD between C4X Discovery and AstraZeneca

C4X Discovery Holdings plc has signed an exclusive worldwide licensing agreement with AstraZeneca. It is worth up to $402 million, for its NRF2 Activator program. AstraZeneca will develop and commercialize an oral therapy, C4XD. This is for the treatment of inflammatory and respiratory diseases with a lead focus on chronic obstructive pulmonary disease (COPD). C4X Discovery will receive […]

November 28, 2022 - 3 minutesmins - By Liza Laws

News and Trends 22 Nov 2022

Achilles Therapeutics receives US patent for immunotherapies

A U.S. patent has been granted to Achilles Therapeutics plc for the treatment of patients with an immunotherapy, including vaccine, antibody and autologous T cell therapy approaches, targeting clonal neoantigens identified using the Achilles Clonality Engine (ACE). ACE is a proprietary method for determining clonality of patient-specific mutations that drives the PELEUS bioinformatics platform. Clonal […]

November 22, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 21 Nov 2022

FMRP – the protein behind immunotherapy resistance

Immunotherapy is a cutting-edge approach to treating cancer by turning the patient’s own immune system against their tumor. Despite success rates, immunotherapy has time and again met with a stubborn obstacle: tumor cells often evade the “radar” of immune cells seeking to destroy them. This in turn leads to treatment resistance, which in many cases […]

November 21, 2022 - 6 minutesmins - By Jim Cornall

News and Trends 18 Nov 2022

MIF invests in KAHR to explore lead immunotherapy drug for multiple myeloma

KAHR Medical, a clinical stage biotech company that is developing a treatment for solid tumors and blood cancers has received investment from the Myeloma Investment Fund (MIF). MIF has made the investment to explore the potential of DSP107, KAHR’s leading immunotherapy drug candidate for the treatment of multiple myeloma. “We are thrilled to partner with […]

November 18, 2022 - 3 minutesmins - By Liza Laws

brain cancer glioblastoma divide and conquer

News and Trends 18 Nov 2022

NW Bio reports positive top-line results from phase 3 glioblastoma trial

Northwest Biotherapeutics, which is developing DCVax personalized immune therapies for solid tumor cancers, yesterday (November 17) reported that both median and long tail survival were increased in both newly diagnosed and recurrent glioblastoma. The brain tumor cancer patients were treated with DCVax-L and in its phase 3 clinical trial met both the primary and secondary […]

November 18, 2022 - 4 minutesmins - By Liza Laws

News and Trends 15 Nov 2022

First patient dosed in Nouscom colorectal cancer study

Nouscom, a clinical stage immuno-oncology company developing off-the-shelf and personalized immunotherapies, says the first patient has been dosed in a randomized phase 2 clinical trial evaluating NOUS-209 in combination with anti-PD1 checkpoint inhibitor (CPI) pembrolizumab versus pembrolizumab alone. NOUS-209 is an off-the-shelf immunotherapy targeting 209 specific neoantigens for the treatment of mismatch repair/microsatellite instable high […]

November 15, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 14 Nov 2022

Nutcracker Therapeutics sees anti-tumor responses of lead mRNA immunotherapy

Nutcracker Therapeutics, Inc. has presented the first set of preclinical data for its lead oncology mRNA therapeutic, NTX-250, at the 37th annual Society for Immunotherapy of Cancer meeting. The company said the data demonstrate that NTX-250 has the ability to elicit strong anti-tumor responses in C3.43 murine tumor models and induce an immune response in […]

November 14, 2022 - 3 minutesmins - By Jim Cornall

More News! 8 Nov 2022

ISA Pharmaceuticals’ Amplivant adjuvant boosts immune response in SLP immunotherapy

ISA Pharmaceuticals B.V, a Netherlands-based clinical stage biotech developing immunotherapies to treat cancers and infectious diseases has had a phase 1 clinical study published. The study, using ISA Pharmaceuticals’ Amplivant adjuvant and synthetic long peptide (SLP) therapeutic vaccine technology was published by Leiden University Medical Centre (LUMC) in the Journal for ImmunoTherapy for Cancer. It […]

November 8, 2022 - 2 minutesmins - By Liza Laws

Knowledge hub

Categories

10 oncology deals in 2025 spotlight where industry leaders are betting big

10 biotech companies leading the way in Denmark

Approaches

Therapeutic areas

Webinar: Advancements in antimalarial drug discovery and development

Six psychedelic drug companies aiming to revolutionize mental health treatment

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

10 oncology deals in 2025 spotlight where industry leaders are betting big

10 biotech companies leading the way in Denmark

Webinar: Advancements in antimalarial drug discovery and development

Six psychedelic drug companies aiming to revolutionize mental health treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Immunotherapy

Beyond Biotech podcast 25: Center for Global Development, Humacyte, Transgene

Touchlight and Odimma Therapeutics sign deal to develop personalized cancer therapy

Pictor receives $5M in funding for Covid antibody test and human and animal portfolios

Lyvgen and Bristol Myers Squibb commitment to transform cancer care

Licensing agreement signed for C4XD between C4X Discovery and AstraZeneca

Achilles Therapeutics receives US patent for immunotherapies

FMRP – the protein behind immunotherapy resistance

MIF invests in KAHR to explore lead immunotherapy drug for multiple myeloma

NW Bio reports positive top-line results from phase 3 glioblastoma trial

First patient dosed in Nouscom colorectal cancer study

Nutcracker Therapeutics sees anti-tumor responses of lead mRNA immunotherapy

ISA Pharmaceuticals’ Amplivant adjuvant boosts immune response in SLP immunotherapy

Subscribe to our newsletter to get the latest biotech news!

10 oncology deals in 2025 spotlight where industry leaders are betting big

10 biotech companies leading the way in Denmark

Webinar: Advancements in antimalarial drug discovery and development

Six psychedelic drug companies aiming to revolutionize mental health treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

10 oncology deals in 2025 spotlight where industry leaders are betting big

10 biotech companies leading the way in Denmark

Webinar: Advancements in antimalarial drug discovery and development

Six psychedelic drug companies aiming to revolutionize mental health treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!